+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Corticosteroids Inhalation Formulation Market - Global Forecast 2026-2032- Product Image
Corticosteroids Inhalation Formulation Market - Global Forecast 2026-2032- Product Image
New

Corticosteroids Inhalation Formulation Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081116
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The corticosteroids inhalation formulation market is undergoing continuous transformation, led by device innovation, regulatory shifts, and increasing focus on sustainability. As strategic direction becomes more critical, senior decision-makers must anticipate changes and align portfolios to respond to evolving clinical and market demands.

Market Snapshot: Corticosteroids Inhalation Formulation Market

The corticosteroids inhalation formulation market expanded from USD 5.38 billion in 2025 to USD 5.78 billion in 2026, and is projected to achieve a compound annual growth rate (CAGR) of 8.66%, reaching USD 9.63 billion by 2032. Growth is supported by strong demand for advanced asthma and COPD management, ongoing product innovation, and a shift toward patient-centric and sustainable solutions. Manufacturers are prioritizing designs that optimize clinical outcomes while addressing environmental and regulatory requirements that impact product adoption across diverse geographies.

Scope & Segmentation: Key Pillars of Market Differentiation

  • Formulation Types: Encompasses pressurized metered-dose inhalers (with suspension and solution options), dry powder inhalers, and nebulized corticosteroid formats, enabling adaptation to varying patient preferences and care environments.
  • Device Engineering: Prioritizes inhaler performance, human factors, and digital-health integration to enhance dosing reliability and minimize operational errors in real-world use.
  • Therapeutic Positioning: Includes monotherapies, fixed-dose combinations, and triple therapies, each supporting either incremental or comprehensive respiratory care approaches.
  • Dosage Strengths & Regimens: Offers step-up/step-down dosing flexibility to adapt to individualized care pathways, while integrating consistent device designs to drive adherence.
  • Patient Groups: Addresses the clinically distinct requirements of pediatric, adult, and geriatric populations, factoring in dosing accuracy, safety, and device usability for each cohort.
  • Distribution Channels: Spans hospital pharmacies, retail outlets, online platforms, and homecare, each requiring tailored patient education, packaging, and adherence strategies.
  • Regional Coverage: Includes the Americas, Europe, Middle East & Africa, and Asia-Pacific, each influenced by diverse policy frameworks, supply chain dynamics, and clinical practices.
  • Environmental Focus: Integrates advancements in propellants, material selection, and packaging sustainability, driven by regulatory requirements and procurement preferences for greener products.

Key Takeaways: Strategic Insights for Decision-Makers

  • Innovative device platforms with superior usability increasingly serve as differentiators, particularly for populations with varying inspiratory flow rates and specialized administration needs.
  • Evidence generation, including real-world adherence data and patient-reported outcomes, is a critical requirement for market access and reimbursement negotiations with both regulators and payers.
  • Sustainability initiatives, such as the transition to alternative propellants and recyclable materials, are becoming non-negotiable for both commercial success and regulatory compliance.
  • Tailored segmentation across formulation, device type, patient demographics, and channel selection is required to achieve alignment with clinical practice and supply chain efficiency.
  • Robust supply chain frameworks, featuring diversified sourcing and regional assembly, contribute to portfolio resilience and mitigate potential disruptions in specialized component supply.
  • Integrated drug-device platforms, regulatory alignment, and high-performing supplier relationships are key to building and sustaining competitive advantage in respiratory care innovation.

Tariff Impact: Navigating Policy-Driven Disruption

Forthcoming U.S. tariff measures have the potential to affect the cost structure for inhaled corticosteroid offerings, especially in procurement of device parts such as valves, canisters, and advanced plastics. To minimize operational risk, manufacturers are focusing on sourcing diversification, expanded safety stock, and expedited supplier onboarding. Additional responses include pursuing localized production, standardizing component specifications, and strengthening partnerships to ensure reliability. These developments may also prompt manufacturers to reevaluate their contracting and promotional approaches in order to protect their higher-value portfolios and adapt to price pressures.

Methodology & Data Sources

Findings in this report are drawn from analysis of current technical literature, structured interviews with industry stakeholders, and triangulation of regulatory, commercial, and manufacturing datasets. This methodology ensures that insights are current, peer-validated, and tested for consistency.

Corticosteroids Inhalation Formulation Market: Why This Report Matters

  • Provides actionable guidance to help executive teams navigate emerging requirements in device engineering, regulation, and procurement, supporting adaptive investment strategies.
  • Presents practical market segmentation and regional insights, allowing leaders to optimize product strategies for local market and clinical realities.
  • Outlines pathways to sustainable growth by highlighting how companies can meet shifting environmental standards, demonstrate product value, and ensure supply continuity.

Conclusion

Senior leadership teams can use this analysis to refine corticosteroid inhalation strategies and address fast-moving dynamics in product development, regulatory compliance, and supply chain management. Prioritizing integrated innovation, adaptability, and forward-looking business models positions portfolios for sustained market leadership.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Corticosteroids Inhalation Formulation Market, by Indication
8.1. Asthma
8.2. COPD
9. Corticosteroids Inhalation Formulation Market, by Dosage Form
9.1. Dry Powder Inhaler
9.2. Metered Dose Inhaler
9.3. Nebulizer
9.3.1. Jet Nebulizer
9.3.2. Mesh Nebulizer
9.3.3. Ultrasonic Nebulizer
9.4. Soft Mist Inhaler
10. Corticosteroids Inhalation Formulation Market, by Molecule
10.1. Beclomethasone
10.2. Budesonide
10.3. Ciclesonide
10.4. Fluticasone
10.5. Mometasone
11. Corticosteroids Inhalation Formulation Market, by End User
11.1. Adult
11.2. Pediatric
12. Corticosteroids Inhalation Formulation Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Corticosteroids Inhalation Formulation Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Corticosteroids Inhalation Formulation Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Corticosteroids Inhalation Formulation Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Corticosteroids Inhalation Formulation Market
17. China Corticosteroids Inhalation Formulation Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AstraZeneca PLC
18.6. Bausch Health Companies Inc.
18.7. Boehringer Ingelheim International GmbH
18.8. Chiesi Farmaceutici S.p.A.
18.9. Cipla Limited
18.10. Dr. Reddy’s Laboratories Limited
18.11. GlaxoSmithKline plc
18.12. Glenmark Pharmaceuticals Limited
18.13. Hikma Pharmaceuticals PLC
18.14. Johnson & Johnson
18.15. Kyowa Kirin Co., Ltd.
18.16. LEO Pharma A/S
18.17. Liquidia Technologies, Inc.
18.18. Lupin Limited
18.19. Mallinckrodt plc
18.20. Merck & Co., Inc.
18.21. Novartis AG
18.22. Orion Corporation
18.23. Pfizer Inc.
18.24. Sanofi S.A.
18.25. Sun Pharmaceutical Industries Limited
18.26. Sunovion Pharmaceuticals Inc.
18.27. Teva Pharmaceutical Industries Ltd
18.28. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY JET NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY JET NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY JET NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MESH NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MESH NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MESH NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ULTRASONIC NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ULTRASONIC NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ULTRASONIC NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY CICLESONIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY CICLESONIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY CICLESONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY FLUTICASONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOMETASONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOMETASONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOMETASONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 94. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 96. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. EUROPE CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 108. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 109. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 110. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. AFRICA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 123. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 124. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 125. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. ASEAN CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 131. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 132. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. GCC CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 144. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 145. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 146. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. BRICS CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 151. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 152. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 153. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. G7 CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 158. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 159. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 160. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. NATO CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 171. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 173. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
TABLE 174. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 175. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. CHINA CORTICOSTEROIDS INHALATION FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Corticosteroids Inhalation Formulation market report include:
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • LEO Pharma A/S
  • Liquidia Technologies, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.63 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Corticosteroids Therapy Market - Global Forecast 2026-2032 - Product Image

Corticosteroids Therapy Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Inhaler Corticosteroid Device Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Inhaler Corticosteroid Device Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 106 Pages
  • Global
From
Corticosteroids Therapy - Global Strategic Business Report - Product Image

Corticosteroids Therapy - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Nasal Corticosteroid Sprays Market - Global Forecast 2026-2032 - Product Image

Nasal Corticosteroid Sprays Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Corticosteroids Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Corticosteroids Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.